Pharmaceutical combination with stable strontium ranelate and its preparations
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of strontium ranelate and a composition, which is applied in the field of strontium ranelate-stabilized pharmaceutical compositions and preparations thereof, can solve problems such as increase in related substances, appearance and color change, etc., and achieves simplified operation and is suitable for large-scale industrial production. , the effect of shortening the synthesis route of raw materials
Inactive Publication Date: 2008-10-29
TIANJIN INSTITUTE OF PHARMA RESEARCH
View PDF3 Cites 8 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Since strontium ranelate is composed of an organic part ranelic acid and two stable non-radioactive strontium atoms, the raw material drug itself is rela
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
example 1
[0037]
[0038] Preparation Process:
[0039] The raw and auxiliary materials are respectively passed through a 100-mesh sieve for subsequent use. Mix the prescription amount of excipients thoroughly first. Add the raw material medicine to the excipients, so that the medicine and the excipients are fully mixed. Add an appropriate amount of trishydroxymethyl aminomethane to the binder containing 2% hypromellose (30% ethanol), add the binder to the mixture to make a soft material, pass through a 20-mesh sieve and granulate , dried in a ventilated oven at 55°C for 2 hours, passed through a 18-mesh sieve to granulate the dry granules, determined the content of intermediates, and pressed into tablets.
example 2
[0041] Chewable Tablet Prescription (100 Tablets)
[0042] Strontium ranelate 100g
[0043] Mannitol 60g
[0044] Microcrystalline Cellulose 10g
[0045] Xylitol 0.1g
[0046] 10% povidone (water) q.s
[0047] Sodium Lauryl Sulfate 0.15g
[0048] Magnesium Stearate q.s
[0049] The preparation process is the same as in Example 1.
[0061] The preparation process is the same as in Example 1.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses a drug composite to promote the stability of strontium ranelate in the preparation. The invention is characterized in that after the effective dosage of the strontium ranelate for treatment is mixed with medicinal excipients, various dosage forms are produced by adding stabilizer. The dosage of the stabilizer refers to the dosage scope of excipients proscribed in the pharmacopoeia. The experiments and studies determine that the weight percentage of the stabilizer in the drug composite is 0.01-5 percent, which is preferred as 0.01-2 percent. The invention with a simple and unique way solves the color change problem of appearance of strontium ranelate or the problem of material increasing resulting from the excipients like citric acid, aspartame and saccharin sodium contained in the preparation; under the condition of not changing the structure of the strontium ranelate, a certain dosage of stabilizer is added into the excipients to achieve the purpose of the stability of the strontium ranelate. The method simplifies the process and saves the cost, and is more suitable for large-scale industrial production.
Description
technical field [0001] The invention relates to a pharmaceutical composition for stabilizing strontium ranelate drug 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-3-thiophene acetate distrontium salt heptahydrate in preparation . Background technique [0002] Strontium Ranelate StrontiumRanelate [0003] Structural formula: [0004] [0005] Molecular formula: C 12 h 6 N 2 o 8 SSr 2 7H20 molecular weight: 639.60 [0006] Osteoporosis is a systemic skeletal disease characterized by low bone mass and degeneration of bone tissue microarchitecture, accompanied by symptoms such as increased bone fragility, susceptibility to fractures, and pain, and is more common in middle-aged and elderly people. Of the fractures, the most common are vertebral fractures, followed by wrist fractures, and hip fractures are the most serious. It is currently estimated that there are 590 million people over the age of 60 in the world, which may exceed the 1 billion mark by 2020, and will ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more